Shauna, My DH does the same thing with designing. He was the Manager of Public Works for the City of Brandon before he went out on his own. He is sooo busy here. I bet if your DH wanted to start his own business he could. It is a very big jump and we did have a few lean years. I was also not working outside the home. Somehow, when they are engineers the desire for their own company is so strong. Thankfully it has worked out for the best here. My DH is swamped with work. If your DH was to start his own company and that does not work out... with the amount of work that you said that Alberta has for engineers... would he not be able to go out and get a job for another engineering firm? And the advantage that he has as a senior project manager is that his name is familiar to the municipalities that he already works for and to the contractors. Just a thought. (Bad thought?) Brenda

Looks like you're OK, Donna. It's going to be double-blinded. ***************** Arena Pharmaceuticals Announces Initiation of Phase 2b Clinical Trial of Its Novel Anti-Obesity Compound SAN DIEGO, June 23 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it started dosing patients in a Phase 2b clinical trial of APD356, Arena's orally administered, internally discovered drug candidate for the treatment of obesity. The trial will evaluate safety and weight loss in approximately 400 obese patients over 12 weeks. In a Phase 2a clinical trial, APD356 demonstrated a highly statistically significant (p=.0002) average weight loss of 2.9 pounds in patients taking the 15 mg dose of APD356 versus 0.7 pounds for the placebo group, and was generally well tolerated at all doses investigated. The Phase 2b clinical trial is a randomized, double-blinded, dose-ranging study being conducted in the United States. Approximately 400 obese patients will be randomized into four groups to evaluate the safety and efficacy of orally administered doses of 10 mg once daily, 15 mg once daily, and 10 mg twice daily (before breakfast and dinner) of APD356 compared to placebo for 12 weeks. The dose of 10 mg twice daily is expected to provide similar peak blood levels as the 15 mg once daily dose, but higher blood trough levels, thereby maintaining higher average drug concentrations in the blood. The second dose will also provide a second peak in drug level to cover the evening hours. In addition to standard safety evaluations, patients will be assessed by echocardiogram prior to enrollment and at the end of the treatment period. Patients will not receive any diet or exercise advice, but will be required to abstain from consuming alcohol. With the exception of the length of the trial, the design of this trial is substantially similar to the design of the four-week Phase 2a study. "We are excited to initiate this Phase 2b trial, especially in light of the positive Phase 2a results we recently reported, and we look forward to reporting the preliminary results from the trial around the end of the year," stated Jack Lief, Arena's President and CEO. "We are also looking forward to soon announcing initial safety and efficacy data from our Phase 1 clinical trials of APD125 for insomnia. In addition to these clinical-stage programs, we are working aggressively to advance other development programs while continuing our partnering efforts." About Obesity Obesity affects tens of millions of adults and children in the U.S. and poses a serious long-term threat to their health and welfare. The number of overweight and obese people has substantially increased over the past several decades. Approximately two-thirds of all adults in the U.S. are obese or overweight. Medical and related costs of obesity in the U.S. were more than $117 billion in 2000. Being obese or overweight is associated with a number of conditions, including heart disease, stroke, diabetes, cancer and osteoarthritis. Medical treatment options for obese and overweight people are currently limited. About APD356 APD356 is a selective agonist of 5-HT2C serotonin receptors, which are located in the hypothalamus, an area of the brain that plays an important role in regulating food intake and metabolism. Discovered by Arena, APD356 is intended to selectively stimulate the 5-HT2C receptor and has approximately 100-fold selectivity in vitro for the 5-HT2C receptor relative to the 5-HT2B receptor. It is hypothesized that activation of the 5-HT2B receptor is associated with the cardiac valvulopathy observed with non-selective serotonergic agents. In addition, APD356 has approximately 15-fold selectivity in vitro for the 5-HT2C receptor versus the 5-HT2A receptor. Arena believes that the 5-HT2A receptor contributes to the potential central nervous system adverse effects associated with non-selective serotonergic agents. Arena expects that the selectivity of APD356 may allow the compound to be dosed at a well-tolerated level that will induce clinically relevant weight loss without the cardiac valvular side effects observed with non-selective serotonergic agents previously used in the treatment of obesity. Arena holds a patent entitled "5-HT2C Receptor Modulators" granted by the European Patent Office relating to novel compounds that modulate the 5-HT2C serotonin receptor. APD356 is covered under the patent. Arena has a similar patent pending in the U.S. and elsewhere. About Arena Pharmaceuticals Arena is a clinical-stage biopharmaceutical company focusing on the discovery, development and commercialization of small molecule drugs in four major therapeutic areas: metabolic, cardiovascular, inflammatory and central nervous system diseases. Arena is developing a broad pipeline of compounds that act on an important class of drug targets called G protein-coupled receptors, or GPCRs, using its proprietary technologies, including CART(TM) (Constitutively Activated Receptor Technology) and Melanophore. Arena's most advanced clinical compound, APD356, a selective 5-HT2C serotonin receptor agonist for the treatment of obesity, is in Phase 2. Arena is also conducting Phase 1 clinical trials on APD125, a compound with a novel mechanism of action (a selective 5-HT2A receptor antagonist) for the treatment of insomnia. Arena has active collaborations with two major pharmaceutical companies, Ortho-McNeil Pharmaceutical, Inc., a Johnson & Johnson company, for the treatment of type 2 diabetes, and Merck & Co., Inc., for the treatment of atherosclerosis and related disorders. Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. CART(TM) is an unregistered service mark of the company. Forward-Looking Statements Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's Phase 2b clinical trial of APD356, including the design and implementation of the trial and expected activities therein, the timing of results from Arena's clinical trials, the effects of administration of APD356, including the expected effects of specific doses of APD356 and APD356's potency, pharmaceutical behavior and expected blood levels, and other statements about Arena's strategy, technologies, preclinical and clinical programs, and ability to develop compounds and commercializing drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the risk that the results of preclinical or clinical trials may not be predictive of future results, Arena's ability to partner APD356, the results of the Phase 2b study and any future studies of APD356, the results of echocardiograms, the timing, success and cost of Arena's research, out-licensing endeavors and clinical studies, Arena's ability to obtain additional financing, and the timing and receipt of payments and fees, if any, from Arena's collaborators, including Ortho-McNeil and Merck. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law. Contacts: Jack Lief President and CEO David Walsey Director, Corporate Communications Arena Pharmaceuticals (858) 453-7200, ext. 1682 Susan Neath Atkins + Associates Media & Investor Relations (858) 527-3486 www.arenapharm.com SOURCE Arena Pharmaceuticals, Inc. 06/23/2005 Web site: http://www.arenapharm.com

I've had two but not at the same time. The first was from Germany and worked out good. She was a real part of the family and we continue to keep in touch with her. She was here in 2001 at the same time as the terror attacks. I know that was a very scary time for her family in Germany. The other was from Brazil and was here in 2005. She was a nightmare and ended up going to live in another state. This was her goal all along. I found that most are from fairly wealthy homes which is why they can afford to come here in the first place. With the German girl, she told me that it cost her parents $18,000 alone for the program costs. She said that this covered her program in Germany (the one she pays to come here) and the program costs for the U.S. It also covered her airfare and her week long introduction course in New York. It did not cover her spending money. Her parents gave her $400 per month. We did not receive any money, but we knew we wouldn't. Also, we read thru many bios and picked the ones we thought would be a fit for our family. The info provided to us had written recommendations from their teachers, parents etc. We did have to do a little bio about our family but I will say that the one from Germany told me that if she would not have accepted us as her American family, then she would not have received another chance, in all likelihood. I wouldn't tell you not to do this because there are great experiences out there. I will say though that if something doesn't seem right, do not hesitate to get the kids out of your home. Also, when it didn't work out with the Brazilian girl, I demanded that they move her out of our school district. Feel free to email me if you have any questions.

Here's a suggestion. It hinges on ditching the side porch. Right now your public rooms (kitchen, living) and your private rooms (bedrooms, bathrooms) are all jumbled up. It's better to have public all together on one side of a small home and private on the other. To achieve this, I drew your kiddo's room + the front bathroom as a master suite. I'm hopeful that closing up the existing doorway and opening a new one across from the vanity is an affordable project. Another bummer about your existing layout is the disconnect between your living spaces including your back yard. To remedy this, I put the kitchen where your master bedroom is. It would be so nice to have one larger, open living space that peeks to the backyard. It's hard to tell if it's feasible, but I thought that by closing off the master bedroom door you could create a closet for a stackable washer/dryer outside the bathroom. I'd enjoy working this out on graph paper if you have a chance to measure your rooms. Yours is one of my favorite kinds of . projects!